Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma
Current Treatment Options in Oncology · 2024-11 · 25 (11) · 1366-1373
DOI: 10.1007/s11864-024-01269-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 17.10.2024. Verfasst von Michael J Robinson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 777, Nashville, TN, 37232, USA. Hauptthemen laut MEDLINE: Osteosarcoma, Neoadjuvant Therapy. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Opinion Statement Osteosarcoma is the most common primary malignant bone tumor in adolescents and adults. The 5-year survival rate is 65% when localized; however, survival drops dramatically to 10-20% in cases of metastatic disease. Therapy for osteosarcoma saw its first significant advancement in the 1970-80’s, with the introduction of our current standard of care, consisting of the neo/adjuvant treatment regimen methotrexate, doxorubicin (Adriamycin), and cisplatin (collectively referred to as MAP) and surgical resection. Since MAP, development of a better therapeutic approach has stalled, creating a plateau in patient outcomes that has persisted for 40 years. Despite substantial research into a variety of pathways for novel treatment options, clinical trials have not produced sizeable improvements in outcomes. In this article, we discuss our current neoadjuvant standard of care therapy, followed by a review of contemporary therapeutic options, including tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), monoclonal antibodies (mAbs), and chimeric antigen receptor (CAR) T cells. Lastly, we consider the challenges hindering the success of novel treatment options and future research directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 777, Nashville, TN, 37232, USA.
- Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 777, Nashville, TN, 37232, USA. elizabeth.j.davis@vumc.org.
Zitieren
APA
Robinson, M. J., & Davis, E. J. (2024). Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma. Current Treatment Options in Oncology, 25(11), 1366-1373. https://doi.org/10.1007/s11864-024-01269-2
Vancouver
Robinson MJ, Davis EJ. Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma. Current Treatment Options in Oncology. 2024;25(11):1366-1373. doi:10.1007/s11864-024-01269-2
BibTeX
@article{Robinson2024,
author = {Robinson, Michael J and Davis, Elizabeth J},
title = {Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma},
journal = {Current Treatment Options in Oncology},
year = {2024},
volume = {25},
number = {11},
pages = {1366--1373},
doi = {10.1007/s11864-024-01269-2}
}
EUVIMED